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Abstract. Immunogenic cell death is a cell death modality 
that stimulates the immune system to combat cancer cells. 
IMMUNEPOTENT CRP (ICRP) is a mixture of substances 
of low molecular weight obtained from bovine spleens that 
exhibits in vitro cytotoxic activity on different tumor cell lines 
and modulates the immune response in vivo. The aim of the 
present study was to determine whether the cytotoxic effect of 
ICRP and its combination with oxaliplatin (OXP) on murine 
melanoma B16F10 cells was due to immunogenic cell death. 
The cytotoxic assay was performed using flow cytometry to 
detect Annexin V and propidium iodide staining, and calre-
ticulin (CRT) exposure. Adenosine triphosphate, heat shock 
protein (HSP) 70, HSP90 and high mobility group box 1 
(HMGB1) release were identified using bioluminescence, 
western blot and ELISA assays, respectively. The present 
in vitro study demonstrated that treatments with ICRP or 
OXP induced cell death in a time-dependent manner, but 
treatment with the combination of ICRP + OXP increased the 
cytotoxic effect following 24 h of treatment. CRT exposure 
and release of adenosine triphosphate (ATP), HSP70, HSP90 
and HMGB1 were induced by treatment with ICRP, and the 
combination of ICRP + OXP increased the exposure and 
release of damage-associated molecular patterns (DAMPs), 
while OXP treatment only induced CRT exposure, ATP and 
HMGB1 release. The in vivo experiments demonstrated that 
administration of tumor-derived DAMP-rich cell lysates 
derived from B16F10 cells treated with ICRP and the 
combination of ICRP + OXP prevented melanoma growth; 
however, OXP treatment did not. These results suggested that 
IMMUNEPOTENT CRP may be used as an agent to increase 
the ability of antitumor drugs to induce immunogenic cell 
death and prevent the growth of melanoma.
Introduction
Immunogenic death is a cell death modality that stimulates 
the innate and adaptive immune system against cell death 
associated antigens, inducing tumor cell immunogenicity. 
Immunogenic cell death (ICD) is characterized by the expo-
sure or release of immunogenic molecules by dying tumor 
cells (1-3), termed damage-associated molecular patterns 
(DAMPs). Certain DAMPs include calreticulin (CRT) 
exposure on the outer surface of the plasma membrane, 
which serves an important function as a phagocytic signal, 
stimulating phagocytes to engulf dead tumor cells (3,4-8). The 
secretion of adenosine triphosphate (ATP) by dying tumor 
cells is an important chemoattractant for macrophages and 
dendritic cells to the site of tumor (3,9-13). The heat shock 
proteins (HSP) 70 and HSP90, and non-histone chromatin 
binding protein high mobility group box 1 (HMGB1) are 
released into the extracellular space and promote the recogni-
tion of tumor cells by dendritic cells by binding to receptors 
on the cell surface, leading to their elimination by the immune 
system (14-19).
It has been suggested that only certain types of cancer 
therapies induce immunogenic cell death in vitro (20-23) and 
in vivo (5,24-29), and that these may be classified into two 
groups. The targets of group I ICD inducers include DNA 
The novel immunomodulator IMMUNEPOTENT CRP 
combined with chemotherapy agent increased the rate of 
immunogenic cell death and prevented melanoma growth
MARIA DEL CARMEN RODRÍGUEZ-SALAZAR1*,  MOISES ARMIDES FRANCO-MOLINA1*,   
EDGAR MENDOZA-GAMBOA1,  ANA CAROLINA MARTÍNEZ-TORRES1,   
PABLO ZAPATA-BENAVIDES1,  JOSE SULLIVAN LÓPEZ-GONZÁLEZ2,   
ERIKA EVANGELINA CORONADO-CERDA1,  JUAN MANUEL ALCOCER-GONZÁLEZ1,   
REYES SILVESTRE TAMEZ-GUERRA1  and  CRISTINA RODRÍGUEZ-PADILLA1
1Department of Immunology and Virology, Biological Sciences Faculty, 
Autonomous University of Nuevo Leon, San Nicolas de los Garza, Nuevo Leon 66455;  
2Lung Cancer Laboratory, National Institute of Respiratory Diseases ‘Ismael Cosio Villegas’, Mexico City 14080, Mexico
Received April 8, 2016;  Accepted March 28, 2017
DOI: 10.3892/ol.2017.6202
Correspondence to: Dr Reyes Silvestre Tamez-Guerra, 
Department of Immunology and Virology, Biological Sciences 
Faculty, Autonomous University of Nuevo Leon, Avenue Pedro de 
Alba s/n, PO Box 46 F, San Nicolas de los Garza, Nuevo Leon 66455, 
Mexico
E-mail: rtamezguerra@gmail.com
*Contributed equally
Key words: immunogenic cell death, damage-associated molecular 
patterns, melanoma, IMMUNEPOTENT CRP, oxaliplatin
RODRÍGUEZ-SALAZAR et al:  IMMUNEPOTENT AND OXALIPLATIN INDUCED DEATH IN MELANOMA 845
and repair machinery proteins, cytosolic proteins, plasma 
membrane or nucleic proteins, which are targeted by chemo-
therapeutic agents including anthracyclines, oxaliplatin (OXP) 
and mitoxantrone; cardiac glycosides, shikonin and ultraviolet 
C irradiation. Group II ICD inducers target the endoplasmic 
reticulum, and include photodynamic therapy with hypericin 
and Coxsackievirus B3 (8,30-34). Certain ICD agents with 
these characteristics are considered to be anti-cancer vaccines, 
and as therapies that prevent residual cancer.
IMMUNEPOTENT CRP (ICRP) is a dialysate of a hetero-
geneous mixture of low-molecular-weight substances released 
from the disintegrated leukocytes of the blood or lymphoid 
tissue obtained from homogenized bovine spleens. ICRP 
exhibits in vitro cytotoxic effects on different tumor cell lines 
and modulates the immune response in vivo (35-40). The aim 
of the present study was to determine whether ICRP or ICRP 
combined with OXP induced ICD and prevented melanoma 
growth.
Materials and methods
Reagents and antibodies. OXP was obtained from Teva 
Pharmaceutical Industries, Ltd. (Petah Tikva, Israel). 
IMMUNEPOTENT CRP was produced by the Department 
of Immunology and Virology, Biological Sciences Faculty, 
Autonomous University of Nuevo Leon (Nuevo Leon, 
Mexico). Propidium iodide staining solution and allophyco-
cyanin (APC)-conjugated Annexin V was obtained from BD 
Pharmingen (BD Biosciences, San Jose, CA, USA). Phyco-
erythin (PE)-conjugated CRT monoclonal antibodies (cat. 
no. ADI-SPA-601PE-F) and IgG1 isotype control monoclonal 
antibodies (cat. no. ADI-SAB-600PE-D) were obtained from 
Enzo Life Sciences (Farmingdale, NY, USA). Mouse mono-
clonal antibodies targeting HSP70 (cat. no. sc-24), HMGB1 
(cat. no. sc-56698), β-actin (cat. no. sc-69879), rabbit poly-
clonal IgG antibody targeting HSP90 α/β (cat. no. sc-7947), 
and secondary antibodies including mouse anti-rabbit (cat. 
no. sc-2357) and goat anti-mouse (cat. no. sc-2005) IgGs conju-
gated to horseradish peroxidase were obtained from Santa 
Cruz Biotechnology, Inc. (Dallas, TX, USA). Complete Halt 
Protease inhibitor cocktail (100X) was obtained from Thermo 
Fisher Scientific, Inc. (cat. no. 87786; Waltham, MA, USA). 
The ENLITEN ATP Assay System Bioluminescence Detec-
tion kit for ATP measurement was obtained from Promega 
Corporation (Madison, WI, USA). The HMGB1 BioAssay 
ELISA kit (mouse; cat. no. 194487) was purchased from US 
Biological Life Sciences (Salem, MA, USA).
Cell line and culture conditions. The murine melanoma B16F10 
cell line was obtained from American Type Tissue Collection 
(Manassas, VA, USA) and was maintained in Dulbecco's 
modified Eagle's medium/F-12 medium 1:1 containing 
2.50 mM L-Glutamine, 15 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid buffer medium (cat. no. SH30023.FS; 
all HyClone; GE Healthcare Life Sciences, Logan, UT, USA) 
supplemented with 10% heat-inactivated fetal bovine serum 
(cat. no. 10082147) and 100 U/ml penicillin/streptomycin (cat. 
no. 15140122; both Gibco; Thermo Fisher Scientific, Inc.). 
The cell line was incubated in a humidified atmosphere with 
5% CO2 at 37˚C.
Cell death assays. B16F10 cells (1x105) were seeded into 
12-well plates and cultured overnight in 5% CO2 at 37˚C. Cells 
were treated with ICRP (1 U/ml), OXP (800 µM) or a combi-
nation of ICRP (1 U/ml) + OXP (800 µM) for 24, 48 and 72 h. 
Following treatment, cells were collected and washed with 
phosphate-buffered saline (PBS) and resuspended in 100 µl 
of 1X binding buffer (0.1 M Hepes pH 7.4, 1.4 M NaCl and 
25 mM CaCl2; Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) supplemented with APC-conjugated Annexin V 
(5 µl/sample) and propidium iodide (1 µl/sample), incubated on 
ice and kept in the dark for 15 min. Flow cytometry analysis 
was performed using an Accuri C6 cytometer; BD Accuri C6 
Software version 1.0.264.21 was used for data analysis (both 
BD Biosciences, San Jose, CA, USA).
Analysis of CRT on the cell surface. Flow cytometry was used 
to determine the level of CRT exposure induced by the treat-
ments. B16F10 cells (1x105) were treated with ICRP (1 U/ml), 
OXP (800 µM) or the combination of ICRP (1 U/ml) + OXP 
(800 µM) for 6, 12, 24, 48 or 72 h. The cells were harvested, 
suspended in 1X PBS with 1% fetal bovine serum and incu-
bated for 1 h at room temperature in the dark with a CRT 
monoclonal antibody (dilution, 1:100), then analyzed.
Western blot analysis. B16F10 cells (5x106) cells were treated 
with ICRP (1 U/ml), OXP (800 µM) or a combination of ICRP 
(1 U/ml) + OXP (800 µM) for 24, 48 and 72 h. Following 
this, supernatants and cells were collected and centrifuged 
at 260 x g for 10 min at room temperature. The cells were 
washed with PBS and homogenized using the SET 2X lysis 
buffer (20 mM Tris pH 6.8, 2 mM EDTA pH 8.0, 300 mM 
NaCl and 4% SDS; Sigma-Aldrich; Merck KGaA) supple-
mented with the Complete Halt protease inhibitor cocktail. 
Protein quantification was performed using a detergent 
compatible Lowry protocol protein assay (cat. no. 5000112; 
Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal 
amounts of soluble proteins (50 µg) were resolved by 12% 
SDS-PAGE and transferred to a nitrocellulose membrane. 
Non‑specific binding sites were blocked by incubating the 
membrane for 1 h at room temperature in TBS-Tween-20 
supplemented with 5% non-fat powdered milk followed 
by overnight incubation at 4˚C with primary antibodies, 
including anti-HSP90 or -β-actin (the internal standard) at 
a dilution of 1:500, or anti-HSP70 or -HMGB1 at a dilu-
tion of 1:400. The antibodies were diluted in 10 ml of 1X 
TBS-0.1% Tween-20 buffer supplemented with 5% w/v BSA. 
Primary antibodies were detected by incubation with mouse 
anti-rabbit or goat anti-mouse IgGs conjugated to horseradish 
peroxidase, diluted to 1:2,000, for 2 h at room temperature. 
The protein bands were visualized using an enhanced 
chemiluminescence western blotting detection kit and high 
performance chemiluminescence film (both GE Healthcare 
Life Sciences).
ATP release assays. Extracellular ATP levels were measured 
in the supernatant of B16F10 cells treated with ICRP (1 U/ml), 
OXP (800 µM) or a combination of ICRP (1 U/ml) + OXP 
(800 µM) for 24, 48 and 72 h by luciferin-based ENLITEN 
ATP assay (Promega Corporation) according to the manu-
facturer's protocol. Chemiluminescence was recorded with a 
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BioTek Synergy microplate reader (BioTek Instruments, Inc., 
Winooski, VT, USA).
HMGB1 release assays. HMGB1 concentration was measured 
in the supernatant of untreated or treated B16F10 cells with 
ICRP (1 U/ml), OXP (800 µM) and the combination of ICRP 
(1 U/ml) + OXP (800 µM) for 24, 48 and 72 h using the 
HMGB1 ELISA kit according to the manufacturer's protocol.
Animals. A total of 20 female C57BL/6 mice were purchased 
from Harlan Laboratories (Mexico City, Mexico). The body 
weight of mice was 23 (±2) g and they were between 6 and 
10 weeks of age. The mice were housed at 25‑29˚C with 
45% humidity and a 12 h light: 12 h dark cycle. Mice were 
provided food and water ad libitum. According to experi-
mental protocols that were approved by the Ethics Review 
Committee for Animal Experimentation of the Biological 
Sciences Faculty, Autonomous University of Nuevo Leon 
(San Nicolas de los Garza, Mexico).
In vivo anti‑tumor vaccination experiments. A total of 
5x106 B16F10 cells were treated with ICRP (3 U/ml), OXP 
(12,600 µM) or a combination of ICRP (1.2 U/ml) + OXP 
(900 µM) for 48 h in vitro. Following this, the cells were 
centrifuged at 260 x g for 10 min and washed twice with PBS. 
Finally, cells were resuspended in 200 µl PBS and inoculated 
subcutaneously into the left flank of the mice. After 7 days, 
mice were challenged with 5x105 live B16F10 cells resuspended 
in 200 µl of PBS via subcutaneous injection into the right flank. 
Tumor incidence and growth were measured every day at the 
two injection sites for 60 days with a digital caliper. Tumor 
volume was calculated using the formula: V=(W (2) x L)/2, 
where V is tumor volume, W is tumor width and L is tumor 
length.
Humane end-points were used to avoid unnecessary 
suffering. Mice were sacrificed when the width of tumors 
reached 20 mm. Effort was made to minimize environmental 
stress. The control group was sacrificed at 20 days, the OXP 
group at 30 days, and the ICRP and ICRP + OXP groups at 
60 days.
Statistical analysis. The experiments were performed in trip-
licate and statistical analysis was performed using a one-way 
analysis of variance followed by Dunnett's test. P<0.05 was 
considered to indicate a statistically significant difference. 
SPSS version 17.0 (IBM Corp., Armonk, NY, USA) was used 
to perform the analysis.
Results
Cell death is induced by ICRP, OXP or ICRP + OXP treat‑
ments in the B16F10 cell line. Treatment with ICRP [24 h 
(30.6%), 48 h (69.6%), and 72 h (85%)] and OXP [24 h 
(50.5%), 48 h (72.6%), and 72 h (88%)] induced cell death 
in a time-dependent manner (Fig. 1A). Treatment with the 
combination of ICRP + OXP induced a cytotoxic effect at all 
time-points evaluated [24 h (98.8%), 48 h (100%), and 72 h 
(100%); Fig. 1A]. Apoptosis was indicated by staining with 
Annexin V-APC, which binds to phosphatidylserine residues 
on the surface of dying cells, and propidium iodide, which 
Figure 1. ICRP, OXP and ICRP + OXP treatments induce cell death in B16F10 cells, as assessed by Annexin V-allophycocyanin and PI staining and analyzed 
by flow cytometry. (A) Representative bar graphs of data obtained via flow cytometry, presented as the mean ± standard deviation and performed in triplicate. 
(B) Data are represented as a dot plot. ICRP, IMMUNEPOTENT CRP; OXP, oxaliplatin; PI, propidium iodide; CTR, control.
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penetrates only into dead cells (Fig. 1B). In the untreated 
B16F10 cells, cell viability was not affected.
CRT exposure is induced by treatment with ICRP, OXP or 
ICRP + OXP in the B16F10 cell line. Treatment with ICRP 
or OXP induced CRT exposure in a time-dependent manner 
(ICRP: 6 h, 9.1%; 12 h, 23%; 24 h, 48.6%; 48 h, 63%; and 72 h, 
77.4%; P<0.001; OXP: 6 h, 2.6%; 12 h, 9.2%; 24 h, 17.7%; 48 h, 
29%; and 72 h, 76.8%; P<0.05; Fig. 2). Treatment with a combi-
nation of ICRP + OXP induced the highest exposure of CRT 
following treatment for 24 h, however, following combined 
treatment for 6 h, CRT exposure was higher compared with the 
individual treatments (6 h, 12.7%; 12 h, 58.2%; 24 h, 85.4%; 
48 h, 85.10%; and 72 h, 90%; P<0.001; Fig. 2).
Release of ATP in the B16F10 cell line following treat‑
ment with ICRP, OXP or ICRP + OXP. The release of ATP 
significantly increased following 24 h of treatment with ICRP 
(P<0.05; Fig. 3) and the combination of ICRP+OXP (P<0.001; 
Fig. 3). Following 48 h of treatment, ATP release was not 
detected except by ICRP treatment at 72 h (P<0.01; Fig. 3). 
The decreased ATP detection following 48 h of treatment may 
be because extracellular ATP is not stable, due to the pres-
ence of various enzymes that degrade ATP (ATPases) or the 
decomposition of ATP to adenosine diphosphate, adenosine 
monophosphate, adenosine and inorganic phosphate (10,13).
Release of HSP70, HSP90 and HMGB1 proteins in the 
B16F10 cell line treated with ICRP, OXP or ICRP+OXP. 
In the supernatant, treatment with ICRP + OXP induced 
the release of HSP70 and HSP90 in the B16F10 cells at all 
evaluated time-points, and their release was increased at 
48 and 72 h relative to 24 h. ICRP treatment induced the 
release of these proteins, and they were detected at 48 h, 
Figure 2. ICRP, OXP and ICRP + OXP treatments induce exposure of calreticulin in B16F10 melanoma cells. Treated cells were stained using anti-calreticulin 
antibodies and isotype control antibodies conjugated with fluorochrome phycoerythrin and analyzed by flow cytometry. Results are from three independent 
experiments performed in triplicate, and data are presented as the mean ± standard deviation. (A) Representative bar graphs of data obtained from flow 
cytometry. *P<0.05, **P<0.001 vs. control. (B) Representative dot plots of the experiment. ICRP, IMMUNEPOTENT CRP; OXP, oxaliplatin.
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and their release was increased in the supernatants at 72 h 
relative to 24 h. OXP did not induce the release of HSP70 or 
HSP90 at any of the evaluated time-points. HMGB1 was not 
detected in any of the treatments by western blotting (Fig. 4). 
Therefore, an ELISA kit with high sensitivity was used for 
its detection, and it was revealed that all ICRP, OXP or ICRP 
Figure 3. ATP release in response to ICRP, OXP, and ICRP + OXP treatments. *P<0.05, **P<0.001 vs. control. ATP, adenosine triphosphate; ICRP, 
IMMUNEPOTENT CRP; OXP, oxaliplatin.
Figure 4. Expression and release of HSP70, HSP90 and HMGB1 proteins in response to treatment with ICRP, OXP, and ICRP + OXP. Western blotting was 
performed using (A) cell supernatants and (B) whole cell lysates of B16F10 cells. β-actin was used as a loading control. HSP, heat shock protein; HMGB1, high 
mobility group box 1; ICRP, IMMUNEPOTENT CRP; OXP, oxaliplatin.
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+ OXP treatments increased HMGB1 release at 24 and 48 h 
compared with the control (P<0.001; Fig. 5). Treatment with 
ICRP significantly increased the release of HMGB1 at 24 h 
(P<0.001) and 48 h (P<0.001) compared with the control; 
however, it decreased at 72 h (P<0.001; Fig. 5). Treatment 
with OXP significantly increased the release of HMGB1 at 
24 h (P<0.05) and 48 h (P<0.001) but decreased the release 
at 72 h compared with the control (Fig. 5). The treatment 
with ICRP + OXP significantly increased the release of 
HMGB1 at all the times evaluated (P<0.001) compared with 
the control. In the cell lysates, the presence of HSP70, HSP90 
and HMGB1 was detected in the control treatment at all the 
time-points evaluated. HSP70 and HSP90 were detected in 
cells exposed to ICRP or ICRP + OXP treatments at 24, 48 
and 72 h, but were not detected in cells exposed to OXP treat-
ment at 72 h. HMGB1 only was detected in cells exposed to 
ICRP treatment at 24 h (Fig. 4).
In vivo effects of tumor‑derived DAMP‑rich cell lysates derived 
from B16F10 cells treated with ICRP, OXP or ICRP + OXP 
in the prevention of melanoma. In vitro experiments demon-
strated the cytotoxic effect and induction of DAMPs, which 
are characteristic of immunogenic cell death, following treat-
ments with ICRP, OXP, or a combination of ICRP + OXP. 
To evaluate the immunogenicity of the immunogenic cell 
death induced by the treatments in vivo, anti-tumor vaccina-
tion experiments were performed in a mouse model. The 
tumor-derived DAMP-rich cell lysates derived from previous 
Figure 6. Effects of tumor-derived DAMP-rich cell lysates derived from B16F10 cells treated with ICRP, OXP, and ICRP + OXP in the prevention of mela-
noma. The tumor‑derived DAMP‑rich cell lysate‑derived treatments of B16F10 cells were subcutaneously inoculated into C57BL/6 mice on the left flank. Mice 
were re‑challenged with live B16F10 cells on the right flank. After 7 days, melanoma growth was evaluated. *P<0.05 vs. control. DAMP, damage-associated 
molecular pattern; ICRP, IMMUNEPOTENT CRP; OXP, oxaliplatin.
Figure 5. HMGB1 release by dying B16F10 cells following treatment with ICRP, OXP, and ICRP + OXP, as assessed by ELISA. The results represent three 
experiments performed in triplicate and data are expressed as the mean ± standard deviation. *P<0.05, **P<0.001 vs. control. HMGB1, high mobility group box 
1; ICRP, IMMUNEPOTENT CRP; OXP, oxaliplatin.
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treatments of B16F10 cells with ICRP, OXP or a combination 
of ICRP + OXP were administered to mice prior to inoculation 
with live B16F10 cells. The results demonstrated that the ICRP 
and ICRP + OXP treatments prevented the development of 
melanoma growth. The tumor-derived DAMP-rich cell lysates 
from the OXP treatment did not protect against melanoma 
growth, but delayed mortality in the mice (30 days) compared 
with the control (20 days; Fig. 6).
Discussion
There has been increasing interest in the optimization of 
old and the identification of novel therapeutic agents with 
the capacity to generate anticancer immunity. Immunogenic 
cell death generated from antitumor treatments is one of 
the mechanisms through which these treatments elicit their 
tumor-targeting immune responses (41). The present study 
aimed to determine the potential of ICRP used in combi-
nation with chemotherapy to increase cytotoxicity against 
tumor cells and to induce molecules associated with immu-
nogenic death, as novel therapeutic regimens that focus on a 
combination of strategies to trigger these mechanisms are in 
development.
The results of the present study demonstrated that treat-
ment with ICRP was cytotoxic in B16F10 melanoma cells, and 
that the combination of ICRP treatment with OXP increased 
the rate of cell death. This was similar to results concerning 
the cytotoxic effects on cancer cells of ICRP treatment alone, 
which were identified previously by our group (37). It is impor-
tant to note that in the present study, the treatments with ICRP 
or ICRP + OXP induced the release of several immunogenic 
molecules (CRT, ATP, HSP70, HSP90 and HMGB1) in vitro. 
The presence of these molecules, when induced by anthracy-
cline treatment in colon cancer CT26 cells, melanoma B16F10 
cells or fibrosarcoma MCA205 cells, has been associated with 
the prevention of tumor growth (42-44). HMGB1 was not 
detected in the supernatant by western blot assay, potentially 
due to the sensitivity of the antibody used; but when examined 
with an ELISA kit with high sensitivity the release of HMGB1 
was detected. Similar results for human HMBG1 were demon-
strated by Nowak et al (45), where concentrations of 150 ng/ml 
were detected by ELISA and western blot, but lower concen-
trations (1 or 15 ng/ml) were not detected by western blot; only 
by ELISA.
OXP treatment has been suggested to induce the release of 
DAMPs (CRT, ATP, HMGB1 and type I interferon) in several 
cancer cell lines, and is considered to be an inductor agent of 
ICD (27,31). To the best of our knowledge, studies examining 
the effect of immunogenic cell death induced by OXP on the 
B16F10 cancer cell line, which is poorly immunogenic, had 
not yet been performed. The results of the present study indi-
cated that oxaliplatin induced the exposure of CRT and the 
release of ATP and HMGB1, but did not induce the release of 
HSP70 and HSP90 in the B16F10 cancer cell line. Compounds 
with the capability to induce the release of HSP70, HSP90, 
ATP and HMGB1 have been demonstrated to prevent tumor 
growth (30-34,46,47). In addition, Chen et al (24) suggested 
that treatment with shikonin in B16F10 cells induced expo-
sure of CRT and the release of HSP70, HSP90, GRP78 and 
HMGB1 in vitro, and allowed the maturation of dendritic 
cells; and shikonin tumor-derived cell lysate-loaded dendritic 
cell vaccines were indicated to induce retardation of tumor 
growth and to increase the survival rate of mice. Similar 
results were obtained in the present study, where tumor 
cell lysates derived from B16F10 cells treated with ICRP 
or ICRP + OXP administered to mice were demonstrated 
to prevent melanoma growth induced by injection with live 
B16F10 cells, indicating the potential of these treatments to 
induce immunogenic cell death. OXP-induced immunogenic 
death of colon cancer cells has been demonstrated in murine 
and human cell lines, and OXP prevented the formation of 
tumors (4,27). However; in the present study this was not 
observed, suggesting that it is necessary for OXP to induce 
the additional release of HSP70 and HSP90 in B16F10 cells in 
order to generate immunogenic cell death, similar to the afore-
mentioned treatments (30-34,48,49). Depending on the type of 
cell death inducer involved, tumor cells may expose or release 
factors that affect their uptake (CRT), maturation (HSP90) 
or antigen presentation by dendritic cells (HMGB1) (46). 
Studies investigating the induction of immunogenic cell death 
by anthracyclines, OXP or ionizing radiation suggest that 
these effects require the presence of DAMPs and their corre-
sponding receptors on antigen-presenting cells for complete 
therapeutic success (46).
It has been demonstrated that in cancer patients or whole 
tumor cells, treatment with drugs including oxaliplatin or doxo-
rubicin (30-34) or physical procedures (47,50-52) may induce 
a specific immune response through tumor antigens that have 
been exposed to dendritic cells, together with DAMP priming 
and the activation of naïve T cells to target tumors (53).
Although additional studies are necessary to understand the 
mechanisms underlying the prevention of melanoma growth, 
the present study demonstrated that IMMUNEPOTENT CRP, 
currently used in Mexico as an adjuvant to the immune system, 
may be used in combination with chemotherapy as a potential 
agent to increase the action of antitumor drugs by inducing 
immunogenic cell death to eliminate residual cancer cells in 
patients, and may generate the development of a whole tumor 
vaccine.
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